Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients

被引:40
作者
Pivot, X
Chamorey, E
Guardiola, E
Magné, N
Thyss, A
Otto, J
Giroux, B
Mouri, Z
Schneider, M
Milano, G
机构
[1] Ctr Antoine Lacassagne, Oncopharmacol Unit, F-06189 Nice 2, France
[2] Ctr Hosp Jean Minjoz, Dept Med Oncol, Besancon, France
[3] Roche Pharmaceut, Neuilly Sur Seine, France
关键词
capecitabine; cisplatin; head and neck cancer; pharmacokinetic study; phase I clinical trial;
D O I
10.1093/annonc/mdg410
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The combination of cisplatin and 5-fluorouracil (5-FU) is considered to be the standard treatment in induction chemotherapy for patients with squamous cell carcinoma of the head and neck. Capecitabine (Xeloda(R)) is an oral fluoropyrimidine that is preferentially activated at the tumoral level, exploiting the higher thymidine phosphorylase activity in tumoral tissue. This phase I trial was conducted in patients with locally recurrent or metastatic head and neck carcinoma. The treatment plan included cisplatin on day I every 21 days, followed by capecitabine twice daily from day 2 to day 15, with a 1-week rest period. Pharmacokinetic investigations concerned plasma measurement of unchanged capecitabine. 5'-deoxy-5-fluorocytidine, 5'-doxifluridine and 5-FU using an optimized high performance liquid chromatography method, and cisplatin measurement in plasma using a limited sampling procedure. Twenty-one patients were included (mean age 61 years, range 46-76 years). Dose (mg/m(2)) increments for cisplatin and capecitabine (b.i.d.), respectively, were as follows: level 1, 80 and 1000 (three patients): level 2. 100 and 1000 ( 12 patients); and level 3, 100 and 1125 (five patients). Dose-limiting toxicities occurring during the first cycle (grade 3) were observed on level 2 (one patient with diarrhea, nausea, vomiting, hand-foot syndrome, one toxic death due to renal failure and neutropenia, one patient with neutropenia) and on level 3 (one patient with diarrhea, one patient with hand-foot syndrome and one patient with neutrothrombocytopenia). Due to delayed side-effects, 14 patients (67%) had repeated cycles every 28 days instead of 21 days as initially planned. Objective response was obtained in seven patients (three complete responses and four partial responses). There was no evidence of pharmacokinetic-pharmacodynamic relationships with the drugs and metabolites investigated. Combination of capecitabine and cisplatin is feasible. with a very promising response rate. The recommended doses for further phase II studies are those of level 2 with cisplatin 100 mg/m(2) on day 1 and capecitabine 1000 mg/m(2) b.i.d. on days 1-14, every 28 days.
引用
收藏
页码:1578 / 1586
页数:9
相关论文
共 28 条
[1]   Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine [J].
Budman, DR ;
Meropol, NJ ;
Reigner, B ;
Creaven, PJ ;
Lichtman, SM ;
Berghorn, E ;
Behr, J ;
Gordon, RJ ;
Osterwalder, B ;
Griffin, T .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) :1795-1802
[2]  
Cassidy J, 1998, CLIN CANCER RES, V4, P2755
[3]   Capecitabine (Xeloda®) in combination with oxaliplatin:: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors [J].
Díaz-Rubio, E ;
Evans, TRJ ;
Tabernero, J ;
Cassidy, J ;
Sastre, J ;
Eatock, M ;
Bisset, D ;
Regueiro, P ;
Baselga, J .
ANNALS OF ONCOLOGY, 2002, 13 (04) :558-565
[4]   RANDOMIZED COMPARISON OF CISPLATIN PLUS FLUOROURACIL AND CARBOPLATIN PLUS FLUOROURACIL VERSUS METHOTREXATE IN ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - A SOUTHWEST-ONCOLOGY-GROUP STUDY [J].
FORASTIERE, AA ;
METCH, B ;
SCHULLER, DE ;
ENSLEY, JF ;
HUTCHINS, LF ;
TRIOZZI, P ;
KISH, JA ;
MCCLURE, S ;
VONFELDT, E ;
WILLIAMSON, SK ;
VONHOFF, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (08) :1245-1251
[5]   Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts [J].
Ishikawa, T ;
Utoh, M ;
Sawada, N ;
Nishida, M ;
Fukase, Y ;
Sekiguchi, F ;
Ishitsuka, H .
BIOCHEMICAL PHARMACOLOGY, 1998, 55 (07) :1091-1097
[6]  
Ishikawa T, 1998, CANCER RES, V58, P685
[7]  
JACOBS C, 1983, CANCER, V52, P1563, DOI 10.1002/1097-0142(19831101)52:9<1563::AID-CNCR2820520904>3.0.CO
[8]  
2-R
[9]   Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer [J].
Kim, TW ;
Kang, YK ;
Ahn, JH ;
Chang, HM ;
Yook, JH ;
Oh, ST ;
Kim, BS ;
Lee, JS .
ANNALS OF ONCOLOGY, 2002, 13 (12) :1893-1898
[10]  
KONO A, 1983, CHEM PHARM BULL, V31, P175